Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01107418 · ClinicalTrials.gov registry record · Phase 1

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

A Phase 1 study of Malignant Melanoma, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 1
Development phase
52
Enrollment target
13
Study locations

NCT01107418: Completed Phase 1 study of Malignant Melanoma, sponsored by Hoffmann-La Roche.

NCT01107418 is a Phase 1 study of Malignant Melanoma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 52 participants, below the 181-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (71% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01107418, a Phase 1 study of Malignant Melanoma, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 1
Development phase
52 participants
Enrollment target
13
Study locations

Study Summary

This open-label study will assess the pharmacokinetics, efficacy and safety of RO5185426 administered as 240mg tablets in previously treated patients with metastatic melanoma. Patients will be randomized to receive one of four dose-levels of RO5185426 \[RG7204; PLEXXIKON; PLX4032\] orally twice daily on days 1 to 15 (morning dose). Starting on day 22, treatment with RO5185426 may be resumed at a dose of 960 mg twice daily and continued until disease progression. Target sample size is \<100 patients.

Conditions Studied

Malignant Melanoma

Interventions

  • DRUG RO5185426

Study Locations (13)

California

  • - La Jolla
  • - San Francisco
  • - Stanford

Illinois

  • - Chicago
  • - Park Ridge

Connecticut

  • - New Haven

Iowa

  • - Sioux City

Nebraska

  • - Omaha

Ohio

  • - Columbus

Rhode Island

  • - East Providence

Virginia

  • - Charlottesville

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2010-05
Est. Completion 2013-02
Phase Phase 1
Hoffmann-La Roche

909 total trials

What the finished NCT01107418 record still lists

NCT01107418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 181-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (71% lower).

The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 1 intervention - of which RO5185426 is the first listed.

NCT01107418 lists 13 locations in 10 states (California, Illinois, Connecticut).

Frequently Asked Questions

What is clinical trial NCT01107418 about?

NCT01107418 is a clinical study titled "A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma". This open-label study will assess the pharmacokinetics, efficacy and safety of RO5185426 administered as 240mg tablets in previously treated patients with metastatic melanoma. Patients will be randomized to receive one of four dose-levels of RO5185426 \[RG7204; PLEXXIKON; PLX4032\] orally twice dail...

What is the current status of trial NCT01107418?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2010-05. Estimated completion is 2013-02.

What conditions does trial NCT01107418 study?

This clinical trial studies the following conditions: Malignant Melanoma.

What interventions are being tested in trial NCT01107418?

The interventions under investigation include: RO5185426 (DRUG).

Who is sponsoring clinical trial NCT01107418?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01107418 being conducted?

This trial has 13 study locations across California, Connecticut, Illinois, Iowa, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01107418's enrollment target sits among peer trials

52 14th of 28 higher than 15 of 28 other Malignant Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01107418, the US trial registry maintained by the National Library of Medicine. NCT01107418 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.